MRC Technology and AstraZeneca have renewed their strategic collaboration focused on the identification and selection of novel drug targets to potentially treat diseases in oncology, inflammation and diabetes. Under the collaboration, MRC has access to AstraZeneca’s compound library for screening against nominated drug targets at MRC.   The companies will combine selected compounds resulting in a library of more than 200,000 compounds available for screening against novel targets. MRC will be re...